000 | 01983 a2200565 4500 | ||
---|---|---|---|
005 | 20250518084425.0 | ||
264 | 0 | _c20201229 | |
008 | 202012s 0 0 eng d | ||
022 | _a2168-6084 | ||
024 | 7 |
_a10.1001/jamadermatol.2019.4897 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aAtalay, Selma | |
245 | 0 | 0 |
_aComparison of Tightly Controlled Dose Reduction of Biologics With Usual Care for Patients With Psoriasis: A Randomized Clinical Trial. _h[electronic resource] |
260 |
_bJAMA dermatology _c04 2020 |
||
300 |
_a393-400 p. _bdigital |
||
500 | _aPublication Type: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 |
_aAdalimumab _xadministration & dosage |
650 | 0 | 4 | _aAdult |
650 | 0 | 4 | _aAged |
650 | 0 | 4 |
_aBiological Products _xadministration & dosage |
650 | 0 | 4 |
_aDermatologic Agents _xadministration & dosage |
650 | 0 | 4 | _aDrug Tapering |
650 | 0 | 4 |
_aEtanercept _xadministration & dosage |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 | _aNetherlands |
650 | 0 | 4 | _aProspective Studies |
650 | 0 | 4 |
_aPsoriasis _xdrug therapy |
650 | 0 | 4 | _aQuality of Life |
650 | 0 | 4 | _aSeverity of Illness Index |
650 | 0 | 4 | _aTreatment Outcome |
650 | 0 | 4 |
_aUstekinumab _xadministration & dosage |
700 | 1 | _avan den Reek, Juul M P A | |
700 | 1 | _aden Broeder, Alfons A | |
700 | 1 | _avan Vugt, Lieke J | |
700 | 1 | _aOtero, Marisol E | |
700 | 1 | _aNjoo, Marcellus D | |
700 | 1 | _aMommers, Johannes M | |
700 | 1 | _aOssenkoppele, Paul M | |
700 | 1 | _aKoetsier, Marjolein I | |
700 | 1 | _aBerends, Maartje A | |
700 | 1 | _avan de Kerkhof, Peter C M | |
700 | 1 | _aGroenewoud, Hans M M | |
700 | 1 | _aKievit, Wietske | |
700 | 1 | _ade Jong, Elke M G J | |
773 | 0 |
_tJAMA dermatology _gvol. 156 _gno. 4 _gp. 393-400 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1001/jamadermatol.2019.4897 _zAvailable from publisher's website |
999 |
_c30625931 _d30625931 |